TORONTO, June 4 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation , a leader in the area of buccal drug delivery, announced today that Dr. Itamar Raz, one of the principal investigators in the Company's on-going clinical trials of Oralin(TM), its oral insulin spray formulation, will make a presentation at the American Diabetes Association 64th Annual Meeting & Scientific Sessions. The event takes place June 4-8, 2004 at the Orange County Convention Center, located in Orlando, Florida. The presentation, titled "Pharmacodynamics and Pharmacokinetics of Dose Ranging Effects of Oralin(TM) versus s.c. Regular Insulin in Healthy Volunteers", is scheduled for Friday, June 4, 2004 in Room Valencia A from 2 p.m. to 4 p.m. as part of the Glucose Monitoring and Insulin Delivery Oral Session in the Clinical Diabetes/Therapeutics Category.
The American Diabetes Association is the nation's leading nonprofit health organization providing diabetes research, information and advocacy. The mission of the ADA is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
About Generex
Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery -- delivery to the oral cavity for absorption through the inner mouth mucosa -- of drugs that historically have been administered only by injection. Generex's buccal delivery technology has application to a large number of drugs.
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Biotechnology CorporationCONTACT: Shayne Gilliatt of Generex Biotechnology Corporation,1-800-391-6755 or +1-416-364-2551; or Ken Sgro of CEOcast, Inc.,+1-212-732-4300, or kensgro@ceocast.com, for Generex BiotechnologyCorporation